Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0H2AM
|
||||
| Former ID |
DIB011094
|
||||
| Drug Name |
XR-3054
|
||||
| Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Terminated | [1] | ||
| Company |
Xenova Group plc
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
C1(O[C@@]2(CO1)CC[C@@H](C(=C)C)CC2)(C)C
|
||||
| CAS Number |
CAS 247090-97-7
|
||||
| Target and Pathway | |||||
| Target(s) | Protein farnesyltransferase beta subunit | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Terpenoid backbone biosynthesis | ||||
| Biosynthesis of antibiotics | |||||
| NetPath Pathway | TSH Signaling Pathway | ||||
| Reactome | Inactivation, recovery and regulation of the phototransduction cascade | ||||
| WikiPathways | Visual phototransduction | ||||
| References | |||||
| REF 1 | XR3054, structurally related to limonene, is a novel inhibitor of farnesyl protein transferase. Eur J Cancer. 1999 Jun;35(6):1014-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.